Research Insight

Aevi Genomic Medicine, Inc. announced that it has obtained the right to exercise an exclusive global license for MEDI2338, a Phase 2-ready fully human monoclonal antibody (mAb) that targets interleukin 18 (IL-18). The Company plans to initially develop MEDI2338...

Russia’s increasing reliance on pharmaceutical-driven healthcare is resulting in a growing consumer demand for drugs of all types. Over the past few decades, the country’s domestic pharmaceutical market has shifted, maturing into a model more closely aligned with those of...

Lonza and AllCells have entered into a private label partnership for the manufacture and global commercialization of an extensive range of hematopoietic primary cells. This partnership expands Lonza’s broad offering of hematopoietic cell lines and enables...

New findings from a Giellepi Health Science Division clinical research trial demonstrates that a mixture of probiotic strains and lactoferrin could aid in reducing the most common cause of vaginal discomfort in women. Bacterial vaginosis (BV)...

WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations, announces the expansion of its facilities in San Diego, California. WuXi AppTec’s newly expanded facility will establish a...

Eisai Co., Ltd  and University College London   announced  that they have commenced preparations for Phase I clinical studies on E2814 The first clinical candidate from their drug discovery collaboration, in Alzheimer’s disease patients within fiscal 2018....

ADC Biotechnology , announces that it has secured additional funding of £2.5 million from existing investors and company management. The investment syndicate consists of Maven Capital Partners, Seneca Partners, the Development Bank of Wales and Downing...